Loading live market data…

HCA Healthcare, Inc.

NYSE:HCA

$363.6 USD

-$27.14 (-6.95%)

Volume
4.56M
Average Volume
1.51M
Market Capitalization
$80.66B
P/E Ratio
12.43
Dividend Yield
0.83%
Price Target
$520.00
Year High
$556.52
Year Low
$330.00
Day High
Day Low
Payout Ratio
$0.10
Current Ratio
$0.83
Source Headline
HCA Healthcare Trims 2026 Profit Outlook, Stock Falls

HCA Healthcare Inc.'s (NYSE:HCA) stock is trading lower on Tuesday after cutting its fiscal 2026 earnings guidance from $29.10-$31.50 to $28.70-$30.50.

benzinga.com - 2026-07-14 09:41:48

HCA Healthcare Stock Falls as Uninsured Patients and Declining Surgeries Dent Outlook

HCA Healthcare stock falls after the hospital chain operator lowers its full-year profit outlook as uninsured patients rise in the second quarter.

barrons.com - 2026-07-14 09:16:00

HCA Healthcare Shares Drop After Quarterly Earnings Squeezed by Payer Mix Shifts

The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.

wsj.com - 2026-07-14 09:08:00

HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call

HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Ce

gurufocus.com - 2026-07-14 08:00:00

HCA Healthcare Previews Second Quarter 2026 Results

[url="]HCA Healthcare, Inc.[/url] (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preli

gurufocus.com - 2026-07-14 08:00:00

HCA reports preliminary quarterly revenue above expectations

HCA Healthcare ​on ‌Tuesday reported preliminary second-quarter revenue ​above ​Wall Street ⁠expectations.

reuters.com - 2026-07-14 07:49:41

HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, [email protected] If you are unable to listen during the live webcast, the call will be.

businesswire.com - 2026-07-14 07:35:00

HCA Healthcare Previews Second Quarter 2026 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company's quarterly financial and accounting procedures. HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare.

businesswire.com - 2026-07-14 07:30:00

Is the Options Market Predicting a Spike in HCA Healthcare Stock?

Investors need to pay close attention to HCA stock based on the movements in the options market lately.

zacks.com - 2026-07-08 13:21:03

This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-07-08 08:24:10

Top 50 High-Quality Dividend Growth Stocks For July 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing potentially undervalued by my free cash flow model.

seekingalpha.com - 2026-07-08 07:42:40

HCA Healthcare's Fall Shouldn't Be Construed As Failing Health

HCA Healthcare remains a soft 'buy' despite recent underperformance, with fundamentals improving and shares attractively priced on an absolute basis. HCA's revenue and profitability continue to grow, driven by Medicare/Medicaid, increased equivalent admissions, and higher revenue per admission, even as the physical footprint shrinks. Management sustains shareholder returns through dividends and aggressive buybacks, with a 6.9% reduction in share count and $9.18 billion in remaining buyback capacity.

seekingalpha.com - 2026-07-07 22:20:41

Your Hospital’s HR Won’t Tell You This: Nurses Can Legally Shield $49,000 a Year by Stacking a 403(b) and a 457(b)

Your hospital's benefits packet lists a 403(b), and it may also quietly list a 457(b) on a separate page. Human resources rarely explains what happens when a nurse funds both: the IRS treats them as separate buckets, not one aggregate limit. That is the loophole. For nurses employed by nonprofit hospitals, public health systems, or... Your Hospital's HR Won't Tell You This: Nurses Can Legally Shield $49,000 a Year by Stacking a 403(b) and a 457(b)

247wallst.com - 2026-07-07 17:13:53

Can HCA's Capacity Expansion Strategy Fuel Its Long-Term Growth?

HCA is expanding hospitals, ERs and outpatient sites while investing billions in new capacity to support future healthcare demand and long-term growth.

zacks.com - 2026-07-07 13:25:56

Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

zacks.com - 2026-07-06 10:30:35

Can HCA's Gene Therapy Milestone Drive Long-Term Growth?

HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.

zacks.com - 2026-07-01 14:06:05

HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b.

businesswire.com - 2026-06-29 08:30:00

HCA Healthcare (HCA) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-26 10:46:07

Why HCA Healthcare (HCA) is a Top Stock for the Long-Term

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

zacks.com - 2026-06-25 10:31:12

Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-24 10:41:33

Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit

The May Jobs report told a familiar story for investors in healthcare stocks. The sector added 35,200 positions last month, led by ambulatory health services at 25,700 and hospitals at 6,000.

marketbeat.com - 2026-06-15 09:50:25

Is HCA Undervalued? DCF Says Worth $765

On June 10, 2026, we present a detailed DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance context with a yea

gurufocus.com - 2026-06-10 07:03:00

Mission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the understanding, diagnosis, and treatment of disease. The announcement comes ahead of the upcoming Human Cell Atlas General Meeting 2026, taking place June 16–18 in Boston, where Mission Bio will participate alongside leading researchers and.

businesswire.com - 2026-06-09 09:00:00

Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting

WALTHAM, Mass.--(BUSINESS WIRE)-- #HCA--Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset in neurodegenerative brain tissue using MERFISH 2.0™ chemistry on the MERSCOPE Ultra Platform at the Human Cell Atlas (HCA) General Meeting, June 16-18, in Boston. The company will also launch Volumetric Tissue Mapping services and a new Cell Atlasing Hub, a central resource for the cell atlasing communi.

businesswire.com - 2026-06-08 08:00:00

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

seekingalpha.com - 2026-06-08 04:51:11

3 Beaten-Down Stocks to Buy and Hold Forever

Don't wait too long to buy the dip on these stocks.

fool.com - 2026-06-02 04:15:00

HCA Healthcare to Acquire CHCP to Strengthen Workforce Development

HCA plans to acquire CHCP, expanding healthcare education efforts and boosting its pipeline of trained professionals across hospitals and care sites.

zacks.com - 2026-05-28 11:01:20

HCA Healthcare Announces Agreement to Acquire The College of Health Care Professions

NASHVILLE, Tenn. & HOUSTON--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, and The College of Health Care Professions (CHCP), one of the largest allied healthcare training providers in Texas, today announced an agreement for HCA Healthcare to acquire ownership of CHCP. CHCP provides healthcare education to more than 8,000 students annually across 10 campuses throughout Texas and online. “The College of Health Care Professions has built a stro.

businesswire.com - 2026-05-27 16:30:00

Is HCA Undervalued? DCF Says Worth $765

On May 27, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance with a year-to-date dec

gurufocus.com - 2026-05-27 07:36:00

HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-20 14:11:01

HCA Healthcare Colleagues Volunteer More Than 41,800 Hours During Annual Days of Service Initiative

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced the results of its seventh annual We Show Up for Our Communities days of service volunteer initiative. In alignment with National Volunteer Month, HCA Healthcare colleagues across the country donated their time and expertise to help improve the health and well-being of the communities the company serves. “Caring for our communities is at the heart of HCA Healthca.

businesswire.com - 2026-05-19 08:30:00

HCA DCF Analysis: Intrinsic Value $765 vs Price $423

On May 19, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has experienced a price performance of -0.8% over the past week, -1

gurufocus.com - 2026-05-19 07:36:00

HCA DCF Analysis: Intrinsic Value $765 vs Price $429

On May 08, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has seen varied price performance recently. Over the past week, the

gurufocus.com - 2026-05-08 07:53:00

HCA Healthcare, Inc. to Present at May Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: May 20, 2026, at 11:30am ET at the RBC Global Healthcare Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Invest.

businesswire.com - 2026-04-30 16:30:00

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-04-30 09:56:13

Comerica Bank Sells 3,248 Shares of HCA Healthcare, Inc. $HCA

Comerica Bank reduced its position in shares of HCA Healthcare, Inc. (NYSE: HCA) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,860 shares of the company's stock after selling 3,248 shares during the period. Comerica Bank's holdings in

defenseworld.net - 2026-04-29 14:23:15

HCA Healthcare Inc (HCA) Shares Surge 3.1% -- What GF Score of 97 Tells Investors

On April 27, 2026, HCA Healthcare Inc (HCA) shares rose 3.1% today, bringing the current price to $445.77. Over the past year, the stock has experienced a notab

gurufocus.com - 2026-04-27 17:04:00

HCA Healthcare Names Cynthia Cifuentes-Finkel Senior Vice President of Marketing and Corporate Affairs

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare (NYSE: HCA) today announced that Cynthia Cifuentes-Finkel has been named senior vice president of marketing and corporate affairs, effective June 8, 2026. She will report to Mike McAlevey, executive vice president, chief legal and administrative officer, and will lead enterprise marketing, corporate communications, and stakeholder engagement in support of HCA Healthcare's enterprise growth priorities. “Cynthia is a strategic and accomplished lea.

businesswire.com - 2026-04-27 17:00:00

These Analysts Slash Their Forecasts On HCA Healthcare After Q1 Results

HCA Healthcare Inc. (NYSE:HCA) posted in-line earnings for the first quarter on Friday.

benzinga.com - 2026-04-27 10:40:04

HCA Announces Proposed Public Offering of Senior Notes

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. Actual terms of the senior notes, including maturity, interest rate and principal amount, will depend on market conditions at the time of pricing. HCA Inc. intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of outstanding borrowing.

businesswire.com - 2026-04-27 08:24:00

HCA Healthcare, Inc. $HCA Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC decreased its holdings in HCA Healthcare, Inc. (NYSE: HCA) by 3.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,373 shares of the company's stock after selling 1,964 shares during the quarter. Calamos Advisors LLC's holdings in HCA Healthcare

defenseworld.net - 2026-04-25 03:58:55

HCA Healthcare, Inc. (NYSE:HCA) Given Consensus Rating of “Moderate Buy” by Analysts

HCA Healthcare, Inc. (NYSE: HCA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-four ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to

defenseworld.net - 2026-04-25 02:30:51

HCA Healthcare Inc (HCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges

Revenue Increase: 4.3% compared to the first quarter last year.Adjusted EBITDA Increase: Almost 2% year-over-year.Diluted Earnings Per Share (Adjusted): Increa

gurufocus.com - 2026-04-25 02:04:00

HCA Healthcare: Policy Pressures May Be Limiting Admissions (Upgrade)

HCA Healthcare is upgraded to "Hold" after a 12% pullback, and is now trading near fair value with a 7% free cash flow yield. Q1 results were mixed: EPS matched expectations, revenue grew 4%, but surgical volumes softened and margins retraced 50 bps. Policy headwinds, including Medicaid and ACA subsidy rollbacks, are expected to temper growth to 2%-3% annually over the next several years.

seekingalpha.com - 2026-04-24 14:42:41

HCA Healthcare, Inc. (HCA) Q1 2026 Earnings Call Transcript

HCA Healthcare, Inc. (HCA) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-24 14:31:36

HCA Healthcare Q1 Earnings Miss Estimates on Rising Expenses

HCA's Q1 EPS misses estimates as rising expenses and weaker surgeries weigh despite modest revenue growth and gains in ER visits.

zacks.com - 2026-04-24 12:50:57

HCA Healthcare (HCA) Faces Decline After Q1 Results and FY26 Guidance

HCA Healthcare (HCA) is experiencing a significant drop in trading following its Q1 earnings report and reaffirmation of FY26 guidance. The mixed results stem p

gurufocus.com - 2026-04-24 12:14:00

HCA (HCA) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-04-24 10:33:02

HCA Healthcare (HCA) Q1 Earnings and Revenues Miss Estimates

HCA Healthcare (HCA) came out with quarterly earnings of $7.15 per share, missing the Zacks Consensus Estimate of $7.17 per share. This compares to earnings of $6.45 per share a year ago.

zacks.com - 2026-04-24 09:10:24

Is HCA Healthcare (HCA) Overvalued After Q1 2026 EPS Miss and Revenue Beat? EPS $7.15 vs $7.18 est; Revenue $19.109B vs $19.103B est -- GF Score 95/100, GF Valuation: 9.9% Overvalued

On April 24, 2026, HCA Healthcare Inc (HCA) released its 8-K filing reporting financial and operating results for the first quarter ended March 31, 2026. The co

gurufocus.com - 2026-04-24 07:31:00

Get HCA Insider Trade Alerts

HCA Price Target Summary

Last Month

$471.60

5 analysts

Last Quarter

$484.67

15 analysts

Last Year

$496.69

49 analysts

All Time

$382.64

110 analysts

HCA Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-13 Wells Fargo Maintain Equal Weight Equal Weight
2026-07-08 Barclays Downgrade Overweight Equal Weight
2026-07-07 Cantor Fitzgerald Maintain Overweight Overweight
2026-06-22 TD Cowen Maintain Buy Buy
2026-06-04 Bernstein Maintain Market Perform Market Perform
2026-04-27 Barclays Maintain Overweight Overweight
2026-04-27 TD Cowen Maintain Buy Buy
2026-04-27 Truist Securities Maintain Buy Buy
2026-04-27 Stephens & Co. Maintain Overweight Overweight
2026-04-27 RBC Capital Maintain Outperform Outperform
2026-04-27 Wells Fargo Maintain Equal Weight Equal Weight
2026-04-27 Keybanc Maintain Overweight Overweight
2026-04-27 Oppenheimer Maintain Outperform Outperform
2026-03-10 TD Cowen Maintain Buy Buy
2026-02-25 Mizuho Maintain Outperform Outperform
2026-02-23 UBS Maintain Buy Buy
2026-02-20 JP Morgan Maintain Neutral Neutral
2026-02-06 Argus Research Maintain Buy Buy
2026-01-30 Wells Fargo Maintain Equal Weight Equal Weight
2026-01-28 RBC Capital Maintain Outperform Outperform
2026-01-28 Cantor Fitzgerald Maintain Overweight Overweight
2026-01-28 Deutsche Bank Maintain Buy Buy
2026-01-28 Barclays Maintain Overweight Overweight
2026-01-28 Truist Securities Maintain Buy Buy
2026-01-28 Oppenheimer Maintain Outperform Outperform
2026-01-28 Jefferies Maintain Buy Buy
2026-01-28 Keybanc Maintain Overweight Overweight
2026-01-28 UBS Maintain Buy Buy
2026-01-07 Wells Fargo Maintain Equal Weight Equal Weight
2025-12-18 Mizuho Maintain Outperform Outperform
2025-12-15 Morgan Stanley Downgrade Equal Weight Underweight
2025-11-13 Wells Fargo Maintain Equal Weight Equal Weight
2025-10-28 Jefferies Maintain Buy Buy
2025-10-27 Mizuho Maintain Outperform Outperform
2025-10-27 Barclays Maintain Overweight Overweight
2025-10-27 Stephens & Co. Maintain Overweight Overweight
2025-10-27 Truist Securities Maintain Buy Buy
2025-10-27 Goldman Sachs Maintain Buy Buy
2025-10-27 UBS Maintain Buy Buy
2025-10-27 B of A Securities Maintain Neutral Neutral
2025-10-27 RBC Capital Maintain Outperform Outperform
2025-10-27 Oppenheimer Maintain Outperform Outperform
2025-10-27 TD Cowen Maintain Buy Buy
2025-10-27 Keybanc Maintain Overweight Overweight
2025-10-17 Mizuho Maintain Outperform Outperform
2025-10-14 UBS Maintain Buy Buy
2025-10-08 Keybanc Maintain Overweight Overweight
2025-10-07 Wells Fargo Maintain Equal Weight Equal Weight
2025-10-07 Cantor Fitzgerald Maintain Overweight Overweight
2025-09-18 Barclays Maintain Overweight Overweight
2025-09-10 B of A Securities Maintain Neutral Neutral
2025-08-26 Cantor Fitzgerald Maintain Overweight Overweight
2025-08-14 Baird Maintain Neutral Neutral
2025-08-14 Wells Fargo Maintain Equal Weight Equal Weight
2025-08-04 JP Morgan Maintain Neutral Neutral
2025-07-28 Wolfe Research Downgrade Outperform Peer Perform
2025-07-28 Morgan Stanley Maintain Equal Weight Equal Weight
2025-07-28 RBC Capital Maintain Outperform Outperform
2025-07-28 Barclays Maintain Overweight Overweight
2025-07-16 Truist Securities Maintain Buy Buy
2025-07-16 B of A Securities Downgrade Buy Neutral
2025-06-23 RBC Capital Maintain Outperform Outperform
2025-06-09 Morgan Stanley Maintain Equal Weight Equal Weight
2025-06-02 Barclays Maintain Overweight Overweight
2025-05-29 Wells Fargo Upgrade Underweight Equal Weight
2025-05-13 B of A Securities Maintain Buy Buy
2025-04-28 RBC Capital Maintain Outperform Outperform
2025-04-15 Baird Downgrade Outperform Neutral
2025-01-27 Barclays Maintain Overweight Overweight
2025-01-27 Cantor Fitzgerald Maintain Overweight Overweight
2025-01-27 B of A Securities Maintain Buy Buy
2025-01-27 RBC Capital Maintain Outperform Outperform
2025-01-07 Keybanc Maintain Overweight Overweight
2025-01-06 Truist Securities Maintain Buy Buy
2024-12-17 Morgan Stanley Maintain Equal Weight Equal Weight
2024-11-25 Wells Fargo Downgrade Equal Weight Underweight
2024-11-22 Raymond James Downgrade Outperform Market Perform
2024-11-08 Barclays Maintain Overweight Overweight
2024-11-06 Wells Fargo Maintain Equal Weight Equal Weight
2024-10-28 Keybanc Maintain Overweight Overweight
2024-10-28 TD Cowen Maintain Buy Buy
2024-10-28 Oppenheimer Maintain Outperform Outperform
2024-10-22 Wells Fargo Maintain Equal Weight Equal Weight
2024-10-04 Cantor Fitzgerald Maintain Overweight Overweight
2024-10-01 Cantor Fitzgerald Maintain Overweight Overweight
2024-08-23 RBC Capital Maintain Outperform Outperform
2024-08-20 Cantor Fitzgerald Maintain Overweight Overweight
2024-08-19 Cantor Fitzgerald Maintain Overweight Overweight
2024-08-19 Truist Securities Maintain Buy Buy
2024-08-14 UBS Maintain Buy Buy
2024-07-30 Wells Fargo Maintain Equal Weight Equal Weight
2024-07-25 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-24 RBC Capital Maintain Outperform Outperform
2024-07-24 Truist Securities Maintain Buy Buy
2024-07-24 Oppenheimer Maintain Outperform Outperform
2024-07-24 Leerink Partners Maintain Outperform Outperform
2024-07-24 Barclays Maintain Overweight Overweight
2024-07-24 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-10 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-10 Barclays Maintain Overweight Overweight
2024-07-09 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-02 Cantor Fitzgerald Maintain Overweight Overweight
2024-06-28 Deutsche Bank Maintain Buy Buy
2024-05-30 JP Morgan Maintain Neutral Neutral
2024-04-30 TD Cowen Maintain Buy Buy
2024-04-29 Oppenheimer Maintain Outperform Outperform
2024-04-29 Barclays Maintain Overweight Overweight
2024-04-29 RBC Capital Maintain Outperform Outperform
2024-04-12 Deutsche Bank Maintain Buy Buy
2024-04-10 Cantor Fitzgerald Maintain Overweight Overweight
2024-03-28 Wells Fargo Maintain Equal Weight Equal Weight
2024-03-05 Cantor Fitzgerald Maintain Overweight Overweight
2024-01-31 Truist Securities Maintain Buy Buy
2024-01-31 Raymond James Maintain Outperform Outperform
2024-01-31 RBC Capital Maintain Outperform Outperform
2024-01-24 Raymond James Maintain Outperform Outperform
2024-01-19 Cantor Fitzgerald Maintain Overweight Overweight
2024-01-17 Oppenheimer Maintain Outperform Outperform
2024-01-04 Bernstein Downgrade Outperform Market Perform
2023-12-11 Goldman Sachs Downgrade Buy Neutral
2023-11-17 JP Morgan Maintain Neutral Neutral
2023-11-10 Stephens & Co. Maintain Overweight Overweight
2023-10-30 Goldman Sachs Maintain Buy Buy
2023-10-26 Wells Fargo Maintain Equal Weight Equal Weight
2023-10-25 Citigroup Maintain Buy Buy
2023-10-25 Mizuho Maintain Buy Buy
2023-10-25 Raymond James Maintain Outperform Outperform
2023-10-25 Stephens & Co. Maintain Overweight Overweight
2023-10-25 Truist Securities Maintain Buy Buy
2023-10-25 RBC Capital Maintain Outperform Outperform
2023-10-20 Wells Fargo Maintain Equal Weight Equal Weight
2023-09-14 Cantor Fitzgerald Maintain Overweight Overweight
2023-09-13 RBC Capital Maintain Outperform Outperform
2023-07-28 Oppenheimer Maintain Outperform Outperform
2023-07-28 Credit Suisse Maintain Outperform Outperform
2023-07-11 Mizuho Maintain Buy Buy
2023-06-28 Barclays Maintain Equal Weight Equal Weight
2023-06-20 Truist Securities Maintain Buy Buy
2023-05-16 Mizuho Maintain Buy Buy
2023-05-10 Argus Research Maintain Buy Buy
2023-04-25 Bernstein Maintain Outperform Outperform
2023-04-25 Wells Fargo Maintain Equal Weight Equal Weight
2023-04-25 Barclays Maintain Equal Weight Equal Weight
2023-04-24 Credit Suisse Maintain Outperform Outperform
2023-04-24 B of A Securities Maintain Buy Buy
2023-04-24 Raymond James Maintain Outperform Outperform
2023-04-24 TD Cowen Maintain Outperform Outperform
2023-04-24 Jefferies Maintain Buy Buy
2023-04-24 RBC Capital Maintain Outperform Outperform
2023-04-24 Citigroup Maintain Buy Buy
2023-04-24 Loop Capital Maintain Buy Buy
2023-04-24 Deutsche Bank Maintain Buy Buy
2023-04-24 Oppenheimer Maintain Outperform Outperform
2023-04-24 Truist Securities Maintain Buy Buy
2023-04-19 JP Morgan Maintain Neutral Neutral
2023-04-11 Mizuho Maintain Buy Buy
2023-03-16 RBC Capital Maintain Outperform Outperform
2023-03-13 Stephens & Co. Maintain Overweight Overweight
2023-02-23 JP Morgan Maintain Overweight Overweight
2023-02-22 Stephens & Co. Maintain Overweight Overweight
2023-02-13 Argus Research Maintain Buy Buy
2023-02-08 Goldman Sachs Maintain Buy Buy
2023-01-31 Raymond James Maintain Outperform Outperform
2023-01-30 Mizuho Maintain Buy Buy
2023-01-30 RBC Capital Maintain Outperform Outperform
2023-01-30 Cowen & Co. Maintain Outperform Outperform
2023-01-30 Citigroup Maintain Buy Buy
2023-01-30 Truist Securities Maintain Buy Buy
2023-01-19 Oppenheimer Maintain Outperform Outperform
2023-01-13 UBS Maintain Buy Buy
2023-01-03 Wells Fargo Maintain Equal Weight Equal Weight
2022-12-16 SVB Leerink Maintain Outperform Outperform
2022-12-14 Mizuho Maintain Buy Buy
2022-12-12 Goldman Sachs Maintain Buy Buy
2022-11-02 Mizuho Maintain Buy Buy
2022-10-26 Citigroup Maintain Buy Buy
2022-10-25 Raymond James Maintain Outperform Outperform
2022-10-24 Wells Fargo Maintain Equal Weight Equal Weight
2022-10-24 Stephens & Co. Maintain Overweight Overweight
2022-10-24 RBC Capital Maintain Outperform Outperform
2022-10-24 SVB Leerink Maintain Outperform Outperform
2022-10-24 Oppenheimer Maintain Outperform Outperform
2022-09-16 Raymond James Maintain Outperform Outperform
2022-08-24 SVB Leerink Maintain Outperform Outperform
2022-08-02 Mizuho Maintain Buy Buy
2022-07-28 Wells Fargo Maintain Equal Weight Equal Weight
2022-07-26 Raymond James Maintain Outperform Outperform
2022-07-25 SVB Leerink Maintain Outperform Outperform
2022-07-25 RBC Capital Maintain Outperform Outperform
2022-07-25 Truist Securities Maintain Buy Buy
2022-07-25 Credit Suisse Maintain Outperform Outperform
2022-07-15 SVB Leerink Maintain Outperform Outperform
2022-07-12 Goldman Sachs Maintain Buy Buy
2022-07-11 Raymond James Maintain Outperform Outperform
2022-07-07 Deutsche Bank Maintain Buy Buy
2022-07-06 BMO Capital Downgrade Market Perform Underperform
2022-07-01 Mizuho Maintain Buy Buy
2022-06-21 RBC Capital Maintain Outperform Outperform
2022-06-17 Loop Capital Maintain Buy Buy
2022-05-27 Bernstein Upgrade Market Perform Outperform
2022-05-03 Mizuho Maintain Buy Buy
2022-04-26 Raymond James Maintain Outperform Outperform
2022-04-26 UBS Maintain Buy Buy
2022-04-25 Citigroup Maintain Buy Buy
2022-04-25 Credit Suisse Maintain Outperform Outperform
2022-04-25 RBC Capital Maintain Outperform Outperform
2022-04-25 SVB Leerink Maintain Outperform Outperform
2022-04-25 Truist Securities Maintain Buy Buy
2022-04-25 Wells Fargo Maintain Equal Weight Equal Weight
2022-03-29 Wells Fargo Maintain Equal Weight Equal Weight
2022-01-28 SVB Leerink Maintain Outperform Outperform
2022-01-28 Cowen & Co. Maintain Outperform Outperform
2022-01-05 Truist Securities Maintain Buy Buy
2021-12-21 JP Morgan Downgrade Overweight Neutral
2021-12-20 Mizuho Maintain Buy Buy
2021-10-26 Raymond James Maintain Outperform Outperform
2021-10-25 Citigroup Maintain Neutral Neutral
2021-10-25 Credit Suisse Maintain Outperform Outperform
2021-10-25 Oppenheimer Maintain Outperform Outperform
2021-10-25 Stephens & Co. Maintain Overweight Overweight
2021-10-25 RBC Capital Maintain Outperform Outperform
2021-08-12 Barclays Downgrade Overweight Equal Weight
2021-08-06 Goldman Sachs Maintain Buy Buy
2021-07-22 Barclays Maintain Overweight Overweight
2021-07-21 Mizuho Maintain Buy Buy
2021-07-21 Citigroup Maintain Neutral Neutral
2021-07-21 Oppenheimer Maintain Outperform Outperform
2021-07-21 Deutsche Bank Maintain Buy Buy
2021-07-21 Credit Suisse Maintain Outperform Outperform
2021-07-21 Raymond James Maintain Outperform Outperform
2021-07-19 Goldman Sachs Maintain Buy Buy
2021-07-09 Seaport Global Maintain Buy Buy
2021-04-26 Citigroup Downgrade Buy Neutral
2021-04-26 BMO Capital Maintain Market Perform Market Perform
2021-04-23 Raymond James Maintain Outperform Outperform
2021-04-23 RBC Capital Maintain Outperform Outperform
2021-04-23 Deutsche Bank Maintain Buy Buy
2021-04-23 Mizuho Maintain Buy Buy
2021-04-14 Truist Securities Maintain Buy Buy
2021-04-13 Deutsche Bank Maintain Buy Buy
2021-04-09 Mizuho Maintain Buy Buy
2021-02-05 Mizuho Maintain Buy Buy
2021-02-03 Raymond James Maintain Outperform Outperform
2021-02-03 Credit Suisse Maintain Outperform Outperform
2020-12-14 JP Morgan Upgrade Neutral Overweight
2020-11-25 Credit Suisse Maintain Outperform Outperform
2020-11-25 Raymond James Maintain Outperform Outperform
2020-11-25 Mizuho Maintain Buy Buy
2020-11-25 Piper Sandler Maintain Neutral Neutral
2020-10-27 Piper Sandler Maintain Neutral Neutral
2020-10-27 Credit Suisse Maintain Outperform Outperform
2020-10-27 Raymond James Maintain Outperform Outperform
2020-10-27 Mizuho Maintain Buy Buy
2020-10-09 Credit Suisse Maintain Outperform Outperform
2020-09-21 JP Morgan Downgrade Overweight Neutral
2020-09-16 Truist Securities Maintain Buy Buy
2020-07-23 Mizuho Maintain Buy Buy
2020-07-23 Raymond James Maintain Outperform Outperform
2020-07-23 Piper Sandler Maintain Neutral Neutral
2020-07-13 BMO Capital Downgrade Outperform Market Perform
2020-06-11 UBS Maintain Buy Buy
2020-05-20 Citigroup Maintain Buy Buy
2020-04-27 UBS Maintain Buy Buy
2020-04-22 SunTrust Robinson Humphrey Maintain Buy Buy
2020-04-22 Barclays Maintain Overweight Overweight
2020-04-20 Raymond James Maintain Outperform Outperform
2020-04-13 SunTrust Robinson Humphrey Maintain Buy Buy
2020-01-29 RBC Capital Maintain Outperform Outperform
2020-01-29 Baird Maintain Outperform Outperform
2020-01-29 Stephens & Co. Maintain Overweight Overweight
2020-01-29 Citigroup Maintain Buy Buy
2020-01-29 Credit Suisse Maintain Outperform Outperform
2019-12-20 JP Morgan Maintain Overweight Overweight
2019-12-06 B of A Securities Upgrade Neutral Buy
2019-12-06 Bank of America Upgrade Neutral Buy
2019-11-20 Bank of America Maintain Neutral Neutral
2019-10-30 UBS Maintain Buy Buy
2019-10-30 Baird Maintain Outperform Outperform
2019-10-30 Citigroup Maintain Buy Buy
2019-09-06 Bank of America Upgrade Underperform Neutral
2019-09-06 B of A Securities Upgrade Underperform Neutral
2019-07-10 Goldman Sachs Upgrade Neutral Buy
2019-06-24 UBS Maintain Buy Buy
2019-05-01 UBS Maintain Buy Buy
2019-05-01 Deutsche Bank Maintain Buy Buy
2019-04-23 Raymond James Upgrade Market Perform Outperform
2019-04-17 Barclays Maintain Overweight Overweight
2019-01-14 Stephens & Co. Maintain Overweight Overweight
2019-01-03 Deutsche Bank Maintain Buy Buy
2018-11-16 UBS Maintain Buy Buy
2018-11-06 Argus Maintain Buy Buy
2018-11-06 Argus Research Maintain Buy Buy
2018-11-01 Credit Suisse Maintain Outperform Outperform
2018-10-31 Jefferies Maintain Buy Buy
2018-10-12 Citigroup Maintain Buy Buy
2018-10-11 Citigroup Maintain Buy Buy
2018-09-18 Bank of America Maintain Underperform Underperform
2018-09-18 B of A Securities Maintain Underperform Underperform
2018-09-05 BMO Capital Maintain Outperform Outperform
2018-09-05 Morgan Stanley Maintain Underweight Underweight
2018-09-04 Leerink Swann Maintain Outperform Outperform
2018-08-16 Morgan Stanley Maintain Underweight Underweight
2018-08-14 Barclays Maintain Overweight Overweight
2018-07-27 Credit Suisse Maintain Outperform Outperform
2018-07-13 Morgan Stanley Maintain Underweight Underweight
2018-02-01 Morgan Stanley Maintain Underweight Underweight
2018-02-01 BMO Capital Maintain Outperform Outperform
2018-01-31 Wells Fargo Maintain Outperform Outperform
2018-01-31 Leerink Swann Maintain Outperform Outperform
2018-01-31 Credit Suisse Maintain Outperform Outperform
2018-01-04 B of A Securities Downgrade Neutral Underperform
2018-01-04 Bank of America Downgrade Neutral Underperform
2018-01-03 PiperJaffray Downgrade Overweight Neutral
2018-01-03 Piper Sandler Downgrade Overweight Neutral
2017-12-20 Morgan Stanley Downgrade Equal Weight Underweight
2017-11-30 JP Morgan Upgrade Neutral Overweight
2017-11-21 William Blair Maintain Market Perform Perform
2017-11-02 Credit Suisse Maintain Outperform Outperform
2017-11-01 Jefferies Maintain Buy Buy
2017-10-19 BMO Capital Maintain Outperform Outperform
2017-10-19 B of A Securities Maintain Neutral Neutral
2017-10-19 Bank of America Maintain Neutral Neutral
2017-10-19 Baird Maintain Outperform Outperform
2017-10-17 BMO Capital Maintain Outperform Outperform
2017-10-13 Jefferies Maintain Buy Buy
2017-08-22 Baird Maintain Outperform Outperform
2017-08-17 Morgan Stanley Maintain Equal Weight Equal Weight
2017-08-14 Argus Research Maintain Buy Buy
2017-08-14 Argus Maintain Buy Buy
2017-07-26 Morgan Stanley Maintain Equal Weight Equal Weight
2017-07-26 Bank of America Downgrade Buy Neutral
2017-07-26 Citigroup Maintain Neutral Neutral
2017-07-26 B of A Securities Downgrade Buy Neutral
2017-06-28 Argus Research Maintain Buy Buy
2017-06-28 Argus Maintain Buy Buy
2017-06-07 Morgan Stanley Maintain Equal Weight Equal Weight
2017-06-07 Leerink Swann Upgrade Market Perform Outperform
2017-04-05 Deutsche Bank Maintain Buy Buy
2017-03-27 Mizuho Upgrade Neutral Buy
2017-01-04 PiperJaffray Maintain Overweight Overweight
2016-11-09 Avondale Partners Downgrade Market Outperform Market Perform
2016-11-09 Mizuho Downgrade Buy Neutral
2016-10-13 Keybanc Upgrade Hold Overweight
2016-10-13 KeyBanc Upgrade Hold Overweight
2016-09-30 Citigroup Maintain Neutral Neutral
2016-09-23 Evercore ISI Group Maintain Hold Hold
2016-07-29 Citigroup Maintain Neutral Neutral
2016-07-29 JP Morgan Downgrade Overweight Neutral
2016-06-16 Bernstein Maintain Market Perform Perform
2016-04-15 Avondale Partners Maintain Market Outperform Market Outperform
2016-03-24 Credit Suisse Maintain Outperform Outperform
2016-03-14 JP Morgan Upgrade Neutral Overweight
2016-01-29 Credit Suisse Maintain Outperform Outperform
2016-01-06 Barclays Maintain Overweight Overweight
2016-01-06 Longbow Research Downgrade Outperform Market Perform
2016-01-04 Wells Fargo Downgrade Outperform Market Perform
2015-12-17 Goldman Sachs Downgrade Buy Neutral
2015-12-16 Credit Suisse Maintain Outperform Outperform
2015-10-28 Leerink Swann Maintain Outperform Outperform
2015-10-28 Cantor Fitzgerald Maintain Buy Buy
2015-10-15 Jefferies Maintain Buy Buy
2015-10-08 Barclays Maintain Overweight Overweight
2015-09-16 JP Morgan Maintain Neutral Neutral
2015-07-16 Barclays Maintain Overweight Overweight
2015-06-26 Jefferies Maintain Buy Buy
2015-06-26 Wells Fargo Upgrade Market Perform Outperform
2015-06-25 Oppenheimer Maintain Outperform Outperform
2015-06-24 Leerink Swann Maintain Outperform Outperform
2015-06-10 Wedbush Maintain Outperform Outperform
2015-05-06 RBC Capital Maintain Outperform Outperform
2015-05-05 Credit Suisse Maintain Outperform Outperform
2015-04-16 Deutsche Bank Maintain Buy Buy
2015-01-08 Barclays Maintain Overweight Overweight
2015-01-07 Credit Suisse Maintain Outperform Outperform
2015-01-05 Deutsche Bank Maintain Buy Buy
2014-12-18 Sterne Agee Maintain Buy Buy
2014-11-12 Wells Fargo Downgrade Outperform Market Perform
2014-10-29 Citigroup Maintain Buy Buy
2014-10-29 Credit Suisse Maintain Outperform Outperform
2014-10-28 Barclays Maintain Overweight Overweight
2014-10-02 JP Morgan Maintain Overweight Overweight
2014-09-09 Deutsche Bank Maintain Buy Buy
2014-07-30 Citigroup Maintain Buy Buy
2014-07-30 Credit Suisse Maintain Outperform Outperform
2014-07-30 UBS Maintain Buy Buy
2014-07-30 Barclays Maintain Overweight Overweight
2014-07-17 Raymond James Maintain Outperform Outperform
2014-07-17 Deutsche Bank Maintain Buy Buy
2014-06-03 JP Morgan Maintain Overweight Overweight
2014-03-31 Monness Crespi Hardt Maintain Buy Buy
2014-01-15 Raymond James Maintain Outperform Outperform
2013-11-13 BMO Capital Maintain Market Perform Market Perform
2013-10-07 Deutsche Bank Maintain Buy Buy
2013-09-18 Mizuho Upgrade Neutral Buy
2013-07-11 KeyBanc Maintain Hold Hold
2013-05-13 BMO Capital Maintain Market Perform Market Perform
2013-05-03 Credit Suisse Maintain Outperform Outperform
2013-03-25 JP Morgan Maintain Overweight Overweight
2013-03-22 Oppenheimer Maintain Outperform Outperform
2013-03-12 Macquarie Downgrade Outperform Neutral
2013-02-11 Morgan Stanley Maintain Overweight Overweight
2013-02-06 Credit Suisse Maintain Outperform Outperform
2013-02-06 BMO Capital Maintain Market Perform Market Perform
2013-02-04 Jefferies Maintain Buy Buy
2013-01-30 Deutsche Bank Maintain Buy Buy
2013-01-25 UBS Maintain Buy Buy
2013-01-17 Imperial Capital Maintain Outperform Outperform
2012-12-18 JP Morgan Maintain Overweight Overweight
2012-11-07 Goldman Sachs Upgrade Neutral Buy
2012-10-11 Barclays Maintain Overweight Overweight
2012-08-28 Cantor Fitzgerald Maintain Buy Buy
2012-08-20 Imperial Capital Maintain Outperform Outperform
2012-08-07 Jefferies Maintain Buy Buy
2012-08-06 Cantor Fitzgerald Maintain Buy Buy
2012-05-04 Deutsche Bank Maintain Buy Buy
2012-03-23 Cantor Fitzgerald Maintain Buy Buy
2012-02-23 Deutsche Bank Upgrade Hold Buy